Improved method of recombinant AAV2 delivery for systemic targeted gene therapy

Molecular Therapy

Volumn 6, Issue 1, 2002, Pages 106-112

  Mah, Cathryn ^a,b   Fraites Jr , Thomas J ^a,b   Zolotukhin, Irene ^a,b   Song, Sihong ^b   Flotte, Terence R ^a,b   Dobson, Jon ^b,c   Batich, Christopher ^b,c   Byrne, Barry J ^a,b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c University of Florida   (United States)

Author keywords

Dependovirus; Drug carriers; Gene therapy; Microspheres; Vehicles

Indexed keywords

ALPHA 1 ANTITRYPSIN; BETA GALACTOSIDASE; CELL RECEPTOR; GREEN FLUORESCENT PROTEIN; HELICASE; HEPARAN SULFATE; MICROSPHERE; PROTEOGLYCAN; VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ANIMAL TISSUE; ARTICLE; CAPILLARY; CONJUGATION; CONTROLLED STUDY; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; TIME; TISSUE BLOOD FLOW; TISSUE SPECIFICITY; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS RECOMBINANT;

ADENO-ASSOCIATED VIRUS; ADENO-ASSOCIATED VIRUS 2; ANIMALIA; DEPENDOVIRUS;

EID: 0036665607     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1006/mthe.2001.0636     Document Type: Article

References (51)

1. Muzyczka, N. (1992). Use of adeno-associated virus as a general transduction vector for mammalian cells. Curr. Top. Microbiol. Immunol. 158: 97-129.
2. Flotte, T. R., and Carter, B. J. (1995). Adeno-associated virus vectors for gene therapy. Gene Ther. 2: 357-362.
3. Kay, M. A., et al. (2000). Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat. Genet. 24: 257-261.
4. Mittereder, N., March, K. L., and Trapnell, B. C. (1996). Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J. Virol. 70: 7498-7509.
5. Qing, K., et al. (1999). Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat. Med. 5: 71-77.
6. Summerford, C., and Samulski, R. J. (1998). Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J. Virol. 72: 1438-1445.
7. Summerford, C., Bartlett, J. S., and Samulski, R. J. (1999). αVβ5 integrin: a co-receptor for adeno-associated virus type 2 infection. Nat. Med. 5: 78-82.
8. Zolotukhin, S., et al. (1999). Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther. 6: 973-985.
9. Clark, K. R., Voulgaropoulou, F., and Johnson, P. R. (1996). A stable cell line carrying adenovirus-inducible rep and cap genes allows for infectivity titration of adeno-associated virus vectors. Gene Ther. 3: 1124-1132.
10. Kessler, P. D., et al. (1996). Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc. Natl. Acad. Sci. USA 93: 14082-14087.
11. Song, S., et al. (1998). Sustained secretion of human α-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors. Proc. Natl. Acad. Sci. USA 95: 14384-14388.
12. Virella-Lowell, I., Poirier, A., Chesnut, K. A., Brantly, M., and Flotte, T. R. (2000). Inhibition of recombinant adeno-associated virus (rAAV) transduction by bronchial secretions from cystic fibrosis patients. Gene Ther. 7: 1783-1789.
13. Bartlett, J. S., Wilcher, R., and Samulski, R. J. (2000). Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors. J. Virol. 74: 2777-2785.
14. Duan, D., et al. (1999). Dynamin is required for recombinant adeno-associated virus type 2 infection. J. Virol. 73: 10371-10376.
15. Hansen, J., Qing, K., Kwon, H. J., Mah, C., and Srivastava, A. (2000). Impaired intracellular trafficking of adeno-associated virus type 2 vectors limits efficient transduction of murine fibroblasts. J. Virol. 74: 992-996.
16. Hansen, J., Qing, K., and Srivastava, A. (2001). Infection of purified nuclei by adeno-associated virus 2. Mol. Ther. 4: 289-296, doi:10.1006/mthe.2001.0457.
17. Duan, D., et al. (1998). Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue. J. Virol. 72: 8568-8577.
18. Duan, D., Yan, Z., Yue, Y., and Engelhardt, J. F. (1999). Structural analysis of adeno-associated virus transduction circular intermediates. Virology 261: 8-14, doi:10.1006/viro.1999.9821.
19. Vincent-Lacaze, N., et al. (1999). Structure of adeno-associated virus vector DNA following transduction of the skeletal muscle. J. Virol. 73: 1949-1955.
20. Yang, J., et al. (1999). Concatamerization of adeno-associated virus circular genomes occurs through intermolecular recombination. J. Virol. 73: 9468-9477.
21. Miao, C. H., et al. (2000). Nonrandom transduction of recombinant adeno-associated virus vectors in mouse hepatocytes in vivo: cell cycling does not influence hepatocyte transduction. J. Virol. 74: 3793-3803.
22. Russell, D. W., Miller, A. D., and Alexander, I. E. (1994). Adeno-associated virus vectors preferentially transduce cells in S phase. Proc. Natl. Acad. Sci. USA 91: 8915-8919.
23. Ferrari, F. K., Samulski, T., Shenk, T., and Samulski, R. J. (1996). Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J. Virol. 70: 3227-3234.
24. Fisher, K. J., et al. (1996). Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis. J. Virol. 70: 520-532.
25. Qing, K., et al. (1997). Role of tyrosine phosphorylation of a cellular protein in adeno-associated virus 2-mediated transgene expression. Proc. Natl. Acad. Sci. USA 94: 10879-10884.
26. Gossen, M., Bonin, A. L., Freundlieb, S., and Bujard, H. (1994). Inducible gene expression systems for higher eukaryotic cells. Curr. Opin. Biotechnol. 5: 516-520.
27. Loeb, J. E., Cordier, W. S., Harris, M. E., Weitzman, M. D., and Hope, T. J. (1999). Enhanced expression of transgenes from adeno-associated virus vectors with the woodchuck hepatitus virus posttranscriptional regulatory element: implications for gene therapy. Hum. Gene Ther. 10: 2295-2305.
28. Chao, H., et al. (2000). Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. Mol. Ther. 2: 619-623, doi:10.1006/mthe.2000.0219.
29. Davidson, B. L., et al. (2000). Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. Proc. Natl. Acad. Sci. USA 97: 3428-3432.
30. Kaludov, N., Brown, K. E., Walters, R. W., Zabner, J., and Chiorini, J. A. (2001). Adeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity. J. Virol. 75: 6884-6893.
31. Girod, A., et al. (1999). Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2. Nat. Med. 5: 1052-1056.
32. Rabinowitz, J. E., Xiao, W., and Samulski, R. J. (1999). Insertional mutagenesis of AAV2 capsid and the production of recombinant virus. Virology 265: 274-285, doi:10.1006/viro.1999.0036.
33. Shi, W., Arnold, G. S., and Bartlett, J. S. (2001). Insertional mutagenesis of the adeno-associated virus type 2 (aav2) capsid gene and generation of aav2 vectors targeted to alternative cell-surface receptors. Hum. Gene Ther. 12: 1697-1711.
34. Wu, P., et al. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74: 8635-8647.
35. Alexander, I. E., Russell, D. W., Spence, A. M., and Miller, A. D. (1996). Effects of γ irradiation on the transduction of dividing and nondividing cells in brain and muscle of rats by adeno-associated virus vectors. Hum. Gene Ther. 7: 841-850.
36. Mah, C., et al. (1998). Adeno-associated virus type 2-mediated gene transfer: role of epidermal growth factor receptor protein tyrosine kinase in transgene expression. J. Virol. 72: 9835-9843.
37. Russell, D. W., Alexander, I. E., and Miller, A. D. (1995). DNA synthesis and topoisomerase inhibitors increase transduction by adeno-associated virus vectors. Proc. Natl. Acad. Sci. USA 92: 5719-5723.
38. Sanlioglu, S., and Engelhardt, J. F. (1999). Cellular redox state alters recombinant adeno-associated virus transduction through tyrosine phosphatase pathways. Gene Ther. 6: 1427-1437.
39. Chanson, P., et al. (2000). Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly. Clin. Endocrinol. (Oxf.) 53: 577-586.
40. Kharkevich, D. A., Alyautdin, R. N., and Filippov, V. I. (1989). Employment of magnet-susceptible microparticles for the targeting of drugs. J. Pharm. Pharmacol. 41: 286-288.
41. Kovacs, A. F., and Turowski, B. (2002). Chemoembolization of oral and oropharyngeal cancer using a high-dose cisplatin crystal suspension and degradable starch microspheres. Oral Oncol. 38: 87-95.
42. Langer, R. (2000). Biomaterials in drug delivery and tissue engineering: one laboratory's experience. Acc. Chem. Res. 33: 94-101.
43. Rettenmaier, M. A., et al. (1987). Treatment of a syngeneic rat tumor with magnetically responsive albumin microspheres labeled with doxorubicin or protein A. Gynecol. Oncol. 27: 34-43.
44. Kalyanasundaram, S., Feinstein, S., Nicholson, J. P., Leong, K. W., and Garver, R. I., Jr. (1999). Coacervate microspheres as carriers of recombinant adenoviruses. Cancer Gene Ther. 6: 107-112.
45. Baranov, A., et al. (1999). Local and distant transfection of mdx muscle fibers with dystrophin and LacZ genes delivered in vivo by synthetic microspheres. Gene Ther. 6: 1406-1414.
46. D'Ovidio, F., Daddi, N., Suda, T., Grapperhaus, K., and Patterson, A. G. (2001). Efficient naked plasmid cotransfection of lung grafts by extended lung/plasmid exposure time. Ann. Thorac. Surg. 71: 1817-1823.
47. mdx/mdx mice through systemic administration of plasmid DNA. Mol. Ther. 4: 45-51, doi:10.1006/mthe.2001.0419.
48. March, K. L., Madison, J. E., and Trapnell, B. C. (1995). Pharmacokinetics of adenoviral vector-mediated gene delivery to vascular smooth muscle cells: modulation by poloxamer 407 and implications for cardiovascular gene therapy. Hum. Gene Ther. 6: 41-53.
49. Weiss, D. J., Bonneau, L., and Liggitt, D. (2001). Use of perfluorochemical liquid allows earlier detection of gene expression and use of less vector in normal lung and enhances gene expression in acutely injured lung. Mol. Ther. 3: 734-745, doi:10.1006/mthe.2001.0321.
50. Klein, R. L., et al. (1998). Neuron-specific transduction in the rat septohippocampal or nigrostriatal pathway by recombinant adeno-associated virus vectors. Exp. Neurol. 150: 183-194, doi:10.1006/exnr.1997.6736.
51. Song, S., et al. (2001). Stable therapeutic serum levels of human α-1antitrypsin (AAT) after portal vein injection of recombinant adeno-associated virus (rAAV) vectors. Gene Ther. 8: